Moreover, KRAS alterations drive oncogenesis in the majority of pancreatic cancers (73.40%), while a high proportion of biliary tract tumors (25.35%) presents such alterations [12,13]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.